KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Working Capital Changes (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Other Working Capital Changes for 15 consecutive years, with $6.9 million as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes fell 36.12% to $6.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.2 million through Dec 2025, down 31.9% year-over-year, with the annual reading at $13.2 million for FY2025, 31.9% down from the prior year.
  • Other Working Capital Changes for Q4 2025 was $6.9 million at Supernus Pharmaceuticals, down from $11.1 million in the prior quarter.
  • The five-year high for Other Working Capital Changes was $28.2 million in Q2 2023, with the low at -$20.4 million in Q3 2023.
  • Average Other Working Capital Changes over 5 years is $935882.4, with a median of -$728000.0 recorded in 2024.
  • Peak annual rise in Other Working Capital Changes hit 3603.48% in 2023, while the deepest fall reached 1556.33% in 2023.
  • Over 5 years, Other Working Capital Changes stood at -$4.7 million in 2021, then crashed by 97.87% to -$9.2 million in 2022, then rose by 15.22% to -$7.8 million in 2023, then soared by 238.52% to $10.8 million in 2024, then plummeted by 36.12% to $6.9 million in 2025.
  • According to Business Quant data, Other Working Capital Changes over the past three periods came in at $6.9 million, $11.1 million, and $2.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.